leisure time -WSS

leisure time

author：comprehensive 2025-10-01 00:47:09 - browse：1973

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： A new nitrogen execution bill also undermines medical licensing

Wikipedia

WSS

Gene therapy for Afghan refugees’ infant will be fully covered

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Unique patient identifier: Experts argue the benefits, pitfalls

Gene therapy for Afghan refugees’ infant will be fully covered

Problems with a popular proposal to regulate AI in health care

AI gets buy

Wikipedia

leisure time

leisure time

Supreme Court strikes down use of affirmative action

Updated Covid vaccine has 54% effectiveness, new study suggests

DIEP, the 'gold standard' of breast reconstruction, is under threat

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

In Memoriam: Notable people who died in 2023

Dario to buy mental health app maker Twill in cash and stock deal

Heart attack and stroke risk calculators need revising

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Walensky prepares to leave CDC — and Congress — behind

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Wikipedia

AI gets buy

Gene therapy for Afghan refugees’ infant will be fully covered

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Updated Covid vaccine has 54% effectiveness, new study suggests

What’s missing from the debate over nursing home staff minimums

Unique patient identifier: Experts argue the benefits, pitfalls

focus

focus

Wikipedia

hotspot